Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 5/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | NEK7 | Q8TDX7 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9958245 | 0.94 | FLT3 (0.43) | FLT3KITBRAFKDRNEK7 | |
| SCHEMBL25793273 | 0.87 | KIT (0.41) | FLT3KITBRAFKDRNEK7 | |
| SCHEMBL23966921 | 0.81 | FAAH (0.47) | FLT3KITBRAFKDR | |
| SCHEMBL18424542 | 0.81 | KIT (0.44) | FLT3KITBRAFKDRNEK7 | |
| SCHEMBL27217824 | 0.79 | SMN1; SMN2 (0.42) | TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1012949 | 0.76 | BRAF (0.47) | FLT3KITBRAFKDR | |
| SCHEMBL27217912 | 0.75 | SMN1; SMN2 (0.44) | KDRTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL24072584 | 0.75 | CHRNB2 (0.31) | — | |
| SCHEMBL16536880 | 0.74 | KIT (0.56) | FLT3KITKDRNEK7 | |
| SCHEMBL1254926 | 0.73 | NEK7 (0.45) | KITBRAFKDRNEK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4146348-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | FLT3 831/4885KIT 1657/4885BRAF 578/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | FLT3 831/4885KIT 1657/4885BRAF 578/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | FLT3 3082/4885KIT 4277/4885BRAF 1615/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | FLT3 831/4885KIT 1657/4885BRAF 578/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | FLT3 3178/4885KIT 4204/4885BRAF 2323/4885 |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | FLT3 1/4885KIT 4/4885BRAF 75/4885 |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | FLT3 831/4885KIT 1657/4885BRAF 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.